open navigation
Return to News.

Kevin Schmid Appointed as Common Sensing Chief Executive Officer

CAMBRIDGE, Mass., Nov. 29, 2018 — Common Sensing, developer and manufacturer of injectable medicine hardware and software tools, announced the appointment of Kevin Schmid as Chief Executive Officer. Mr. Schmid brings extensive business development and operations leadership experience, having previously served in pivotal roles at Insulet Corporation, Bose Corporation, JDS Uniphase, the Stevanato Group and the Board of Directors of Sorrel Medical Ltd. Mr. Schmid will lead top-level strategy, expansion, and investor relations as Common Sensing commercializes their Gocap smart injectable medicine monitor.

Richard Whalley, President (co-founder) will focus on clinical, quality, and regulatory functions. James White (co-founder) has been appointed Chairman of the Board. “Kevin’s appointment to the chief executive role puts Common Sensing in a very strong position to scale Gocap injector monitoring platforms for insulin and beyond. As we transition from pilot level to commercial level operations over the next year, Kevin’s transformative leadership of the talented and growing Common Sensing team will evolve and drive the execution of our go-to-market strategies for our patented dose sensing technology. Our goal is to provide a smart dose sensing platform for patients, health care providers and payers to embrace injectable medicines for home use,” said James White, Common Sensing Chairman.

A member of Common Sensing’s board of directors since November of 2015 and Chief Operating Officer since January 2018, Kevin is excited to play an expanded role in Common Sensing’s growth. “We are well underway with the development of our high performance, scalable, and commercial Gen 2 Gocap platform. This, combined with insightful user data from existing studies and patients, lays the foundation for Gocap technology to make a tremendous impact on wireless integrated health care. Gocap is an easy-to-use, cost-effective dose monitoring and reporting solution which will be accessible to millions of self-injecting patients,” said Kevin Schmid, Common Sensing Chief Executive Officer.

During his time at Insulet Corporation, Mr. Schmid was instrumental in the development, industrialization, and commercialization of wearable, smart drug delivery pumps, such as the Omnipod Diabetes Management System, the Amgen Neulasta On Body Injector and the Ferring Pharmaceutical LutrePulse System. Millions of patients who do not prefer, or do not have access to, these drug delivery pumps rely on disposable injector pens for delivery of their medication. These pens lack the modern connectivity and data reporting features of drug delivery pumps, which are critical to quality of treatment and improved outcomes for diabetes, infertility, obesity and other indications. Common Sensing’s Gocap retrofits these disposable injector pens into smart injectors integrated with dose sensors, full connectivity and data reporting.

Kevin’s appointment as CEO follows a series of exciting announcements for Common Sensing in 2018. In April Common Sensing closed a Series A financing round. In May Common Sensing signed a development agreement with Haselmeier and signed a development partnership agreement with Flex for the design and development of Gen 2 Gocap commercial platform.

Kevin Schmid – LinkedIn


About Common Sensing

Common Sensing develops and manufactures data-driven hardware and software solutions for people using injectable medicine. Founded in 2012, Common Sensing has assembled a team of talented designers and engineers to develop Gocap™, the first smart cap that turns existing injector pens into smart injectors. Gocap connects insulin, GLP-1, fertility hormone, and human growth hormone injector pens to the cloud to improve outcomes and make everyday treatment more convenient. Based in Cambridge, MA, Common Sensing’s investors include Waterline Ventures, Qualcomm Ventures, Sanofi, Haselmeier, Philips, and New World Health.


PR Newswire